These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 8636755)

  • 1. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial.
    Pont J; Albrecht W; Postner G; Sellner F; Angel K; Höltl W
    J Clin Oncol; 1996 Feb; 14(2):441-8. PubMed ID: 8636755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
    Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
    J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.
    Vidal AD; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    Ann Oncol; 2015 Feb; 26(2):374-7. PubMed ID: 25392157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion.
    Chevreau C; Mazerolles C; Soulié M; Gaspard MH; Mourey L; Bujan L; Plante P; Rischmann P; Bachaud JM; Malavaud B
    Eur Urol; 2004 Aug; 46(2):209-14; discussion 214-5. PubMed ID: 15245815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors.
    Böhlen D; Borner M; Sonntag RW; Fey MF; Studer UE
    J Urol; 1999 Apr; 161(4):1148-52. PubMed ID: 10081858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy.
    Kondagunta GV; Sheinfeld J; Mazumdar M; Mariani TV; Bajorin D; Bacik J; Bosl GJ; Motzer RJ
    J Clin Oncol; 2004 Feb; 22(3):464-7. PubMed ID: 14752068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
    Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
    J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
    Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors.
    Motzer RJ; Sheinfeld J; Mazumdar M; Bajorin DF; Bosl GJ; Herr H; Lyn P; Vlamis V
    J Clin Oncol; 1995 Nov; 13(11):2700-4. PubMed ID: 7595727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study.
    Tandstad T; Cohn-Cedermark G; Dahl O; Stierner U; Cavallin-Stahl E; Bremnes RM; Klepp O
    Ann Oncol; 2010 Sep; 21(9):1858-1863. PubMed ID: 20142410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): a risk adapted protocol of the Hellenic Cooperative Oncology Group.
    Bamias A; Aravantinos G; Kastriotis I; Alivizatos G; Anastasiou I; Christodoulou C; Gyftaki R; Kalofonos HP; Dimopoulos MA
    Urol Oncol; 2011; 29(2):189-93. PubMed ID: 19362863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours.
    Flechtner HH; Fischer F; Albers P; Hartmann M; Siener R;
    Eur Urol; 2016 Mar; 69(3):518-25. PubMed ID: 26620368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy.
    Oliver RT; Ong J; Shamash J; Ravi R; Nagund V; Harper P; Ostrowski MJ; Sizer B; Levay J; Robinson A; Neal DE; Williams M;
    Urology; 2004 Mar; 63(3):556-61. PubMed ID: 15028457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: a prospective trial.
    Pont J; Höltl W; Kosak D; Machacek E; Kienzer H; Julcher H; Honetz N
    J Clin Oncol; 1990 Jan; 8(1):16-20. PubMed ID: 1688613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis.
    Amato RJ; Ro JY; Ayala AG; Swanson DA
    Urology; 2004 Jan; 63(1):144-8; discussion 148-9. PubMed ID: 14751368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.
    de Wit R; Stoter G; Kaye SB; Sleijfer DT; Jones WG; ten Bokkel Huinink WW; Rea LA; Collette L; Sylvester R
    J Clin Oncol; 1997 May; 15(5):1837-43. PubMed ID: 9164193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
    Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
    Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two cycles of carboplatin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial.
    Pectasides D; Skarlos D; Dimopoulos AM; Farmakis D; Pectasides M; Fountzilas G; Aravantinos G
    Anticancer Res; 2003; 23(5b):4239-44. PubMed ID: 14666633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors.
    Christian JA; Huddart RA; Norman A; Mason M; Fossa S; Aass N; Nicholl EJ; Dearnaley DP; Horwich A
    J Clin Oncol; 2003 Mar; 21(5):871-7. PubMed ID: 12610187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy for stage II nonseminomatous germ cell cancer of the testis.
    Kennedy BJ; Torkelson JL; Fraley EE
    Cancer; 1994 Mar; 73(5):1485-9. PubMed ID: 7509255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.